Concurrent Hepatitis C and B Virus and Human Immunodeficiency Virus Infections Are Associated With Higher Mortality Risk Illustrating the Impact of Syndemics on Health Outcomes
Related Experiment Video
Updated: Dec 8, 2025

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
Published on: December 15, 2023
Zahid A Butt1,2,3, Stanley Wong2, Carmine Rossi2
1School of Public Health and Health Systems, University of Waterloo, Waterloo, Ontario, Canada.
Insights
Concurrent infections with Hepatitis C virus (HCV), Hepatitis B virus (HBV), and Human Immunodeficiency Virus (HIV) significantly increase mortality risk. Addressing substance use and comorbidities alongside viral treatments can reduce deaths.
Area of Science:
- Virology
- Epidemiology
- Public Health
Background:
- Hepatitis C virus (HCV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV) are major global health concerns.
- Limited data exist on the mortality risks associated with concurrent infections of these viruses.
- This study investigates the impact of single and multiple viral infections on mortality in British Columbia.
Purpose of the Study:
- To evaluate the effect of HCV, HBV, and HIV infections and coinfections on all-cause mortality.
- To identify factors associated with increased mortality risk in individuals with these viral infections.
- To inform public health strategies for reducing mortality related to viral coinfections.
Main Methods:
- Utilized the BC Hepatitis Testers Cohort, including ~1.7 million individuals tested or reported for HCV, HBV, or HIV from 1990-2015.
- Followed individuals with monoinfection, coinfections, or triple infections from their negative status to death or end of 2016.
- Employed extended Cox proportional hazards regression to determine mortality risk factors and hazard ratios (HRs).
Main Results:
- Out of 658,704 individuals, 33,804 (5.13%) deaths were recorded.
- HCV/HBV/HIV triple infection showed the highest mortality risk (HR, 8.9), followed by HCV/HIV (HR, 4.8), HBV/HIV (HR, 4.1), and HCV/HBV (HR, 3.9).
- Monoinfections also increased mortality risk (HCV: HR 2.6, HBV: HR 2.2, HIV: HR 1.6), with injection drug use, alcohol use, material deprivation, and comorbidities being significant factors.
Conclusions:
- Concurrent multiple viral infections are strongly linked to elevated mortality.
- Substance use, comorbidities, and socioeconomic factors independently contribute to mortality risk.
- Integrated preventive strategies, including harm reduction and coinfection treatment, are crucial for reducing mortality.
Background:
Hepatitis C virus (HCV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV) infections are associated with significant mortality globally and in North America. However, data on impact of concurrent multiple infections on mortality risk are limited. We evaluated the effect of HCV, HBV, and HIV infections and coinfections and associated factors on all-cause mortality in British Columbia (BC), Canada.
Methods:
The BC Hepatitis Testers Cohort includes ~1.7 million individuals tested for HCV or HIV, or reported as a case of HCV, HIV, or HBV from 1990 to 2015, linked to administrative databases. We followed people with HCV, HBV, or HIV monoinfection, coinfections, and triple infections from their negative status to date of death or December 31, 2016. Extended Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for factors associated with all-cause mortality.
Results:
Of 658 704 individuals tested for HCV, HBV, and HIV, there were 33 804 (5.13%) deaths. In multivariable Cox regression analysis, individuals with HCV/HBV/HIV (HR, 8.9; 95% CI, 8.2-9.7) infections had the highest risk of mortality followed by HCV/HIV (HR, 4.8; 95% CI, 4.4-5.1), HBV/HIV (HR, 4.1; 95% CI, 3.5-4.8), HCV/HBV (HR, 3.9; 95% CI, 3.7-4.2), HCV (HR, 2.6; 95% CI, 2.6-2.7), HBV (HR, 2.2; 95% CI, 2.0-2.3), and HIV (HR, 1.6; 95% CI, 1.5-1.7). Additional factors associated with mortality included injection drug use, problematic alcohol use, material deprivation, diabetes, chronic kidney disease, heart failure, and hypertension.
Conclusions:
Concurrent multiple infections are associated with high mortality risk. Substance use, comorbidities, and material disadvantage were significantly associated with mortality independent of coinfection. Preventive interventions, including harm reduction combined with coinfection treatments, can significantly reduce mortality.
Related Concept Videos
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Sexually Transmitted Infections
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Retrovirus Life Cycles
Viral Recombination
Mechanisms of Retrovirus-induced Cancers

